BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sauerwein KMT, Geier CB, Stemberger RF, Akyaman H, Illes P, Fischer MB, Eibl MM, Walter JE, Wolf HM. Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination. Front Immunol 2022;13:827048. [DOI: 10.3389/fimmu.2022.827048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Costa C, Scozzari G, Migliore E, Galassi C, Ciccone G, Ricciardelli G, Scarmozzino A, Angelone L, Cassoni P, Cavallo R; on behalf of the Collaborative Group. Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. Vaccines 2022;10:1031. [DOI: 10.3390/vaccines10071031] [Reference Citation Analysis]
2 Milito C, Cinetto F, Palladino A, Garzi G, Punziano A, Lagnese G, Scarpa R, Rattazzi M, Pesce AM, Pulvirenti F, Di Napoli G, Spadaro G, Carsetti R, Quinti I. Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy. Biomedicines 2022;10:1026. [DOI: 10.3390/biomedicines10051026] [Reference Citation Analysis]
3 Pulvirenti F, Di Cecca S, Sinibaldi M, Piano Mortari E, Terreri S, Albano C, Guercio M, Sculco E, Milito C, Ferrari S, Locatelli F, Quintarelli C, Carsetti R, Quinti I. T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies. Cells 2022;11:1918. [PMID: 35741048 DOI: 10.3390/cells11121918] [Reference Citation Analysis]